West Nile virus DNA vaccine - NIH/Vical

Drug Profile

West Nile virus DNA vaccine - NIH/Vical

Alternative Names: West Nile Virus vaccine - NIH/Vical; WNV vaccine - NIH/Vical

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator National Institutes of Health (USA); Vical
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported West Nile virus infections

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in West Nile virus infections(Prevention) in USA (Injection)
  • 01 Jun 2006 Final results from a phase I clinical trial in West Nile Virus Prevention have been added to the adverse events and viral immunogenicity sections
  • 21 Apr 2005 Phase-I clinical trials in West Nile virus infections prevention in USA (Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top